Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Serina Therapeutics ( (SER) ) has shared an announcement.
On February 11, 2025, Serina Therapeutics announced the appointment of Dr. Jay Venkatesan to its Board of Directors, effective February 12, 2025. Dr. Venkatesan, who has extensive experience in biotechnology investments and strategic growth, will also serve as the Audit Committee Chair. His appointment is expected to bolster Serina’s strategic vision as the company leverages its POZ Platform to develop innovative therapeutics. Concurrently, co-founder Dr. Milton Harris will transition to Director Emeritus and Chair of the Scientific Advisory Board, continuing to guide the company’s research efforts.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates targeting neurological diseases and other indications. Utilizing its proprietary POZ Platform™, Serina aims to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates. The company is based in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology.
YTD Price Performance: -10.71%
Average Trading Volume: 25,932
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $40.9M
See more insights into SER stock on TipRanks’ Stock Analysis page.
